Monthly Archives: June 2008

With the spectacular view from the 14th floor of the T. Boone Pickens Biomedical Building on the UT Southwestern’s campus, Dallas, the IPPF Annual Meeting opened with Dr. Grant Anhalt, Johns Hopkins. Dr. Anhalt helped new patients learn about their disease, giving an overview of autoimmunity, pemphigus, pemphigoid, treatments, and genetic triggers. Dr. Anhalt’s starts our program with his New Patient Orientation lecture, always with great success. It was an eye opener to many that autoimmune diseases are the 3rd most common group of diseases after heart disease and cancer, with billions of dollars being spent each year on treatments. He talked about treatment in general terms, how PNP’s disease looks and acts differently from PV and how all these diseases are clinically different, even though they seem so similar. He described the differences between the pemphigoid diseases as well; how bullous pemphigoid affects people of ages 60+ and that mucous membrane pemphigoid is considered more serious requiring early intervention for success.

Drs. Amit Pandya and Kim Yancey from the University of Texas Southwestern.Dr. Amit Pandya, our UT Southwestern host, officially opened the meeting at 9:15am, introducing David Sirois, IPPF Board President. Dave gave a brief introduction and thanked everyone — participants and speakers — for their enthusiastic participation. He talked about the new Centric/IPPF Health Management Program (HMP), and introduced two new Board members  Rebecca Albrecht and Badri Rengarajan. In celebration of all her efforts for the IPPF Dave presented Janet Segall a certificate from the Texas Governor’s Office for celebrating the Annual meeting in Dallas.

The next speaker introduced by Dr. Pandya was Dr. Victoria Werth, University of Pennsylvania, Philadelphia; Dr. Werth discussed the project funded by the IPPF in 2007 which created the International Pemphigus/Pemphigoid Definitions Committee. The committee consisted of experts on pemphigus/pemphigoid from around the world, who worked together to establish standardized disease descriptions and definitions to allow worldwide documentation and to support a registry and better diagnoses. She explained how important it was to develop common language among researchers when describing disease  what is complete remission, or what the definition of partial remission might be. The first results were described in review, and will be published later this year.

Dr. Werth went on to explain how the use of drug trials are important in helping doctors evaluate and recommend what drugs would be most appropriate to give to patients, in addition to finding new, less burdensome treatments. Recent trials showed that using IV steroids instead of oral steroids did not change outcomes. It has also been shown that that CellCept and Imuran are similar treatments; and new with treatments trials like remicade (infliximab) and the new P38 inhibitor can help evaluate how well a drug might work. Rituximab is now being used to treat pemphigus and pemphigoid, but a trial for PV has not yet been approved. Finally, trials also showed that in the Dapsone study with 9 patients, 73% of people got better and were able to reduce steroids in maintenance.

Patients did their part too, signing up for the new Centric/IPPF HMP (registry), and literally offering up their blood to help the IPPF and its research doctors aid the pursuit of more clinical trials.

Dave Sirois, and Craig Kephardt, CEO of Centric Healthcare, discussed how the questions were developed by the IPPF Medical Advisory Board to methodically register the parameters of disease and the results of treatment protocols, and how the HMP has the added component of providing resource materials for patients along with the opportunity to work with Janet as the peer health coach. This collective (and private) data will help measure the burden of our diseases and treatment outcomes. These data will help doctors and patients manage the disease in the future by minimizing the cost of care, increasing protocol compliance and allowing better communication between the individual and his/her physician.

With the IPPF’s movement into the future, the next to speak was the IPPF’s new CEO, Molly Stuart. Molly is a lawyer by trade, and much of the work she has been involved with was in the non-profit world, including as President of the Random Acts of Kindness Foundation. She asked the participants to educate and inspire her on the specifics of what they (you) see as the programs most meaningful to all.

Next, Dr. Animesh Sinha, Michigan State University, East Lansing, one of the only core researchers in the U.S. on pemphigus and pemphigoid discussed how relevant and important research is. He discussed how antibodies attack protein that holds skin cells together, which causes a split and blisters. He explained that they don’t know all the genes involved, but do know that HLA genes are important genes in regulating the immune system and balance. They found over 91% of patients had either the DR4 (seen in Ashkenasi Jews) or the DQ1 (found mostly in Asian ancestry patients). They looked at different genes and found that another marker Class 1 B and saw that protein HLA E might also be involved in disease development. These are just one set of genes and there are probably many, so they are still looking!! Given this genetic tie, the blood drive became a critical component of the weekend. The goal is a better understanding of the genetics so we can determine who might be at risk.

Although little known about why pemphigus and pemphigoid happen, we do know that there are also environment factors that work together to cause disease process. Researchers are looking for several different trigger factors and believe that investigating different phases of activity will help define how they might find ways from activity to remission. Much of this data will be provided with blood and tissue donations and with trends observed from the registry.

Dr. Pandya explained how because physicians must rely on evidence-based data to make decision on treatment, the decisions that are made in treatment are often based on the experiences of other physicians or from looking at trials with small numbers of patients. Because our diseases are so rare, the clinical data is limited due to lack of patients for clinical trials.

Outlining the steps to effective care, Dr. Pandya noted that it is important that the physician first make the right diagnosis and that it is best if a patient has a doctor who knows about the disease, so that the biopsies are done properly. He recommends that everyone have an internal medicine doctor to help monitor side effects. Other tips included:

  • have good hygiene to keep bacteria away;
  • remember infection is the greatest enemy of people with pemphigus;
  • exercise is important to main muscle mass since prednisone causes weight gain;
  • use roll gauze in wound care and avoid bandages with tape;
  • use antibiotics and, if necessary, consider pain control as well.

The goal of treatment is to stop lesions and clear up the ones there. Some good news is that we do not see high mortality rates any more because there are so many better ways to treat drug side effects. He discussed management of drug therapies, and suggested that side effects will usually occur in patients taking steroids for more than one month. He made it clear that not everyone gets the side effects that are listed on medicine inserts. From a worldwide survey, the immunosuppressive azathioprine (Imuran) is used most often around the world.

Dr. Victoria Werth took the podium again discussing the risks of immunosuppressives, the side effects of drugs and how to minimize complications. Dr. Werth explained that taking steroids once a day may help with side effects and that the longer we take the drugs, more probable it is that we will have side effects. She believes that alternate-day dosing is best and a goal. She emphasized compliance, and said the best way to minimize side effects is with interventions.

  • measure bone density, treat bone loss, and watch lipids and use medication that can help with side effects
  • check glucose, cholesterol, triglycerides, and blood pressure
  • visit the eye doctor and check for increase in eye pressure and watch for cataracts
  • watch for signs of anxiety and depression — commonly experienced as a result of the medications
  • do not stop prednisone without tapering
  • do not get live vaccine if you are on 20 mg of steroids or more
  • avoid activities that can contribute to osteoporosis  alcohol, smoking, etc.
  • if you are on immunosuppressives then get monthly blood tests
  • check liver and blood functions

She encouraged all of us to eat a healthy diet  low salt, low cholesterol, that exercise was critical, and that we should try to minimize weight gain and stress. She was adamant about keeping an eye on herbs that would enhance the immune system and possibly cause flares. Finally, she reminded that it is important to have a medical ID since emergency responders need to know you are on steroids, or have been on steroids within the past few months. Check with your doctor if you notice anything different or unusual happening.

We ate lunch, rested, connected. Door prizes were awarded by our new board member, a very enthusiastic Rebecca Albrecht-Oling. The Q&A followed lunch (see page 12).

Our next speaker, Dr. Kim Yancey, Chairman and Head of the Dermatology Department at UT Southwestern, Dallas, opened the session with a little history explaining that the distinction between pemphigus and pemphigoid was not really made until the 1940s & 1950’s. The focus of his session was Clues Regarding Ocular, Nasal, Laryngeal, Esophageal, and Anogenital Involvement. He gave us an in-depth look at eye involvement with OCP.

He explained that it often feels like sand or grit in the eyes. The eyes would sometimes be shut, and secrete mucous. He said the eyes would be sensitive to sunlight, and there is usually blurred vision. He explained that it usually will start in one eye, but will usually also affect the other as well. One should check for inward growing eye lashes, but if there are questions, a qualified ophthalmologist must look closely at the eye to decide whether the eye is involved.

Dr. Yancey then discussed the nose and nasal passages and that one of the signs of possible involvement was consistent nose bleeds and/or pain. He suggested regular nasal irrigation to keep the area clean, and recommended that the nurses were great resources for all our diseases and the areas affected. He then mentioned the other areas of possible involvement: throat, voice box, and esophagus. Signs to look for in MMP were hoarseness all the time, loss of the voice, severe pain, difficulty swallowing, or feeling like something was stuck in the throat. Sometime reflux could be a symptom, and a person with MMP should watch for problems with respiration. Dr. Yancey then discussed one of the more difficult areas of involvement  genital and anal lesions. The signs to look for were pain and difficulty with bowel or urination. Bleeding could also occur. Erosions are more often found then blisters. Most patients with pemphigus or MMP will not have eye involvement, but some will.

Dr. David Sirois, Professor of Dental Medicine at NYU, New York, discussed the impact of oral lesions. His slides showed how the ulcer on the cheek would be white and not blistered. He explained how important correct biopsies were because if the site for biopsy was incorrect the results can be mistakenly negative for pemphigus or pemphigoid.

He emphasized dental care because gum disease can cause root degeneration and if left untreated can cause a patient to lose teeth. Complications from the drugs can affect the gums and teeth as well. He encouraged patients to watch for candidsis and to use high fluoride if root of tooth is showing. He mentioned that the best toothpaste for oral problems was Prevident 5000, a prescription toothpaste which can be helpful. He encouraged all of us to be educated on what to look for and that prevention is very important. The only solution to restoring teeth is implants and false teeth sitting on mucosal tissue is not good when a person has oral pemphigus or pemphigoid.

Our final speaker of the day was Terry McDonald, Ph.D., a psychologist who talked with us about living and coping with pemphigus and pemphigoid. As a pemphigus patient herself, Terry knows the emotional toll these diseases can have. She discussed how being diagnosed with pemphigus or pemphigoid raises feelings of loss and explained the different stages of loss that one goes through when diagnosed.

Terry talked about her own experience with pemphigus vulgaris and how critical it was to set small goals and to try looking at things differently. There are choices and changes one can make that would impact life. With a diagnosis like ours, we all need to make adjustments. Many need to work to deal with depression, need to find safety, or need to know you belong somewhere. For many, medication can be very helpful. Also, meditation, exercise, and nature can be helpful.

The day’s program ended with a final question and answer session with the doctors. The day was informative and interesting. All the speakers were wonderful, gearing their talks so that we all could understand the information. We left for the day, returning on Sunday.

Sunday opened with the final Q&A session. Caregivers went off together to talk about how they coped living with someone with pemphigus and pemphigoid, and patients got together to give each other support.

The IPPF would like to thank all the patients and patient family members who donated blood at the meeting to Dr. Ani Sinha’s ongoing research into our diseases. By being a part of this project we have a much better chance of finding answers. We hope to continue to support Dr. Sinha’s research at subsequent meetings. Also, cheers to everyone who signed up for the HMP registry. Don’t forget to get your data in!

The 50/50 drawing was won by Dr. Kim Yancey who, in turn, gave his winnings back to the IPPF. We thank Dr. Yancey for his generosity.

Dinner Program

The dinner program began with drinks, hors d’oeuvres, and good conversation, then a terrific (big) Texas-style meal. Certificates of Appreciation went to Joyce Korn for her help in finding the hotel for our dinner and the rooms at great prices, and to Dr. Amit Pandya and Dr. Kim Yancey for the major roles they played in making this meeting a success.

  

Janet Segall presented a Lifetime Achievement Award to Siri Lowe, PV Network founder from the United Kingdom for her dedication to patients and patient advocacy for more than 10 years in the UK. Unfortunately Siri could not be present to accept her award. Janet, to her surprise, was presented with the inaugural Founder’s Award for her efforts over the years on behalf of patient care. A rousing standing ovation followed. Janet was very humbled and still passionate about contributing more. The final award was given to Dr. Robert Jordon, UT Southwestern-Houston. Dr. Jordon along with Dr. Ernest Beutner, SUNY Buffalo pioneered research on immunofluoresence and pemphigus. The IPPF honored Dr. Jordon’s contribution to Immunodermatologic research and his many years of treating and helping blistering disease patients.

Dallas lived up to expectations and has been one of our best meetings ever. Remember to mark your calendars for April 25, 2009 as Los Angeles will be the location for the 12th Annual Patient/Doctor Meeting. We look forward to seeing you there!

 

Many of you already know that my garden is a fundamental aspect of my life. I find each dimension of the garden — the change of seasons, the plants that open in the morning and close at night, the patch of sunlight created when I lost a branch in the storm — to bring its own opportunity for grace. I noticed it this morning in particular, as this bouquet of lovely peach roses dropped its petals after a couple days in our 100 heat. The petals that lay on the counter top however, were the most intense yellowy-pink with deep magenta edges. It was magnificent, the dried, dying petals. Part of the grace that is delivered to me from the garden is a (sometimes forced) appreciation for what is unfolding. So, I’m excited to highlight here, for you, some of the changes that we’ve been putting in place at the IPPF and some of the dreams we hope to make into realities over the next year. I hope you’ll find them to be of benefit to you personally; that you’ll see how they help the IPPF serve more and better; and that you will consider sharing with me your expertise, provided from your perspective as a participant in this organization, so that we may serve in the most meaningful way possible. I know none of you would miss it, but please consider this a jumpstart encouraging you to read Janet’s letter on page 3. There she describes our Health Management Program, the most critical project we are engaged in for 2008. Please offer 30 to 45 minutes of your time to help us document a disease registry that will be the foundation for improved diagnosis, improved treatment protocols, and more extensive research. It’s a small legacy of time that you can leave which will make a huge difference for generations to come. Also, if you do business on the Internet, take a look at the more than 30 hours Will has spent organizing and simplifying our web site at (www.pemphigus.org). All the informational content remains, however the layout is expected to be more clear and intuitive. In addition, I hope you come to enjoy the brighter colors and our new logo, designed to prepare us to catch the attention of grantmakers and corporate partners and pharmaceutical contributors. Finally, we have already started preparations for the 2009 Annual Meeting which will be in Los Angeles April 25, 2009, it’s a great chance to learn, share, console, and laugh. Please continue to join us as we move forward to use the registry as a resource to pursue NIH funding, to train current practitioners in earlier diagnosis and more effective treatments, to support the next generation of dermatologists to gain experience, and to fund and support scientific advances in the effective treatment protocols. And continue to let us know what changes you’d like to see! Warm regards,

Many of you already know that my garden is a fundamental aspect of my life. I find each dimension of the garden — the change of seasons, the plants that open in the morning and close at night, the patch of sunlight created when I lost a branch in the storm — to bring its own opportunity for grace. I noticed it this morning in particular, as this bouquet of lovely peach roses dropped its petals after a couple days in our 100 heat. The petals that lay on the counter top however, were the most intense yellowy-pink with deep magenta edges. It was magnificent, the dried, dying petals. Part of the grace that is delivered to me from the garden is a (sometimes forced) appreciation for what is unfolding.

So, I’m excited to highlight here, for you, some of the changes that we’ve been putting in place at the IPPF and some of the dreams we hope to make into realities over the next year. I hope you’ll find them to be of benefit to you personally; that you’ll see how they help the IPPF serve more and better; and that you will consider sharing with me your expertise, provided from your perspective as a participant in this organization, so that we may serve in the most meaningful way possible.

I know none of you would miss it, but please consider this a jumpstart encouraging you to read Janet’s letter on page 3. There she describes our Health Management Program, the most critical project we are engaged in for 2008. Please offer 30 to 45 minutes of your time to help us document a disease registry that will be the foundation for improved diagnosis, improved treatment protocols, and more extensive research. It’s a small legacy of time that you can leave which will make a huge difference for generations to come.

Also, if you do business on the Internet, take a look at the more than 30 hours Will has spent organizing and simplifying our web site at (www.pemphigus.org). All the informational content remains, however the layout is expected to be more clear and intuitive. In addition, I hope you come to enjoy the brighter colors and our new logo, designed to prepare us to catch the attention of grantmakers and corporate partners and pharmaceutical contributors.

Finally, we have already started preparations for the 2009 Annual Meeting which will be in Los Angeles April 25, 2009, it’s a great chance to learn, share, console, and laugh.

Please continue to join us as we move forward to use the registry as a resource to pursue NIH funding, to train current practitioners in earlier diagnosis and more effective treatments, to support the next generation of dermatologists to gain experience, and to fund and support scientific advances in the effective treatment protocols. And continue to let us know what changes you’d like to see!

Warm regards,

 

We would like to invite you to be part of our new pemphigus/pemphigoid Health Management Program. This program was specifically designed at Centric Health Resources with the help of the IPPF Medical Advisory Board members and staff. With this information, we will be creating a registry of information about the impact of pemphigus/pemphigoid on patients. This will open the door to improved treatments for current patients and provide information to further the chances of finding treatments with less negative impacts — for generations to come.

Many of you already know me as Director of Patient Services for the IPPF and a pemphigus patient myself. I will be your Peer Health Coach and I will be the person you will be talking with to complete the data collection. After you complete the Enrollment and Consent Form and return it to the IPPF, I will call you to set up an appointment to complete our initial survey. During our call, which will take approximately 30-45 minutes, I will ask you specific questions about your disease process: what drugs you are on, if any; what side effects you might be having; additional health problems that might have occurred due to treatment, etc. Depending on where you are with your disease process that will determine any follow-up contacts. We expect that through this relationship and with the additional support materials for you, your caregiver and your doctor, you, personally, will achieve better health and improved quality of life.

This is a voluntary program, but we need your participation to be successful. Your participation is critical to achieving these goals. Whether you have active disease or not, we need you to help us gather information to help future patients with diagnosis, treatment and cure. The Enrollment and Consent Form and a brochure outlining information about the program are on our website at www.pemphigus.org/hmp or we can mail them to you. If you decide to enroll, additional documents will be sent to you. This Health Management Program will help to increase knowledge about pemphigus and pemphigoid, which will ultimately lead to more funding toward research to find a cure.

 

Leadership starts at the top and nowhere is that more evident than with the President of the IPPF’s Board of Directors. Dr. Dave Sirois has been instrumental in leading the Foundation to new levels of success. That being said, having the right people in the right places allows the IPPF to continue forward on our journey to new heights.

Joining the IPPF Board of Directors are Dr. Badri Rengarajan from California and Mrs. Rebecca Albrecht-Oling from New York.

BADRI RENGARAJAN

alt Badri Rengarajan is a member of the Lehman Brothers biotechnology equity research team supporting financial markets evaluation of development- and commercial-stage biotechnology companies.

Badri has over eight years of interdisciplinary experience in business strategy, product development, regulatory/clinical analysis, and investment evaluation. He is responsible for assessing clinical studies and pipeline compounds.

Previously, he was the regulatory lead for several projects in Genentech’s portfolio, including Rituxan (lupus and indolent non-Hodgkins lymphoma), Tarceva (lung and pancreatic cancer), and anti-NGF (pain), for which Badri crafted regulatory strategy, successfully executed several regulatory filings, and negotiated with the FDA. As a member of Genentech’s regulatory intelligence group, Badri synthesized product approval histories for over 100 oncology, cardiovascular, autoimmune, and specialty therapeutics. Badri began his career in management consulting with McKinsey and Company where he served clients in biotechnology, pharmaceuticals, and devices.

Badri earned his bachelor’s degree in Biology and Public Policy from Harvard University and his M.D. from Yale University, where he received a nomination for best thesis project.

REBECCA ALBRECHT-OLING

altRebecca Albrecht-Oling coordinates the Library Instruction Program at Purchase College, State University of New York, which focuses on training students, faculty, and staff how to frame information needs, create effective research strategies, and use the library’s resources to execute those strategies. Rebecca is also the liaison for Assistive Technology needs in the Library (coordinating this with Counseling services and computing services on campus). Her collection development responsibilities include literature and Jewish studies. A graduate of Kent State University (M.L.S.), Kansas State University, (M.A.) and Purdue University, B.A., she writes extensively on literacy and electronic resources.

Rebecca admits she has the Gift of Gab and has been a huge resource in attracting gifts and grants to the IPPF as well as to campus library collections. Rebecca and her husband Scott were a bright addition to our Annual Meeting in Dallas, despite missing their two children.

Nearly all members of the IPPF Medical Advisory Board attended the autoimmune blistering disease meeting in Japan and many gave presentations on new research in pemphigus and pemphigoid. Clinical speakers from the MAB included Dr. Jean-Claude Bystryn, who spoke about rituximab experience in the USA, and Dr. Pascal Joly who spoke on his rituximab experiences in France. General discussion centered around the design of a new clinical trial of rituximab for pemphigus to be conducted in Europe that will be coordinated by Dr. Joly using different dosing schedules.

The other main discussion was about the development of accurate and clinically useful scoring systems for pemphigus and other AIBDs. Dr Michael Hertl, Germany, spoke on a scoring system proposed by the German group, termed the autoimmune bullous disease intensity score (ABSIS), one of the two present scoring systems. Dr. Victoria Werth, USA, presented on the comparison study performed with patients last August at the University of Pennsylvania, in terms of reliability and validity of two outcome instruments for pemphigus, as well as the international Pemphigus Disease Activity Index (PDAI) and the ABSIS.

Dr. Deede Murell (left) and Dr. Victoria Werth.Presentations on the first day covered the pathogenesis of pemphigus and included IPPF MAB members Dr. Luis Diaz and Dr. Sergei Grando. The chairmen of the meeting included Dr. John Stanley and Dr. Masa Amagai. Other world leaders on the causes of pemphigus presented their new work, including scientists Kathy Green (Chicago), Peter Koch (Denver), Andrew Kowalcyk (Atlanta), and Eliane Mueller (Switzerland), along with dermatologists David Rubenstein (Chapel Hill), Carlo Pincelli (Italy), Aimee Payne (Philadelphia), Yumi Aoyoma (Japan), John Zone (Salt Lake City) and Detlef Zillikens (Germany). Topics included signalling pathways, apoptosis, new animal models of blistering diseases and the role of the immune system.

The International Pemphigus Definitions group held a meeting organized by Dr. Dedee Murrell (Australia), with the help of Dr. Takashi Hashimoto (Japan), at which Dr. Werth presented the international photovalidation study that is underway to compare the two different scoring systems using photographs, so that more experts can participate.

Additional participants in these meetings included MAB members Dr. Russell Hall (Durham, NC), and Dr. Neil Korman (Cincinatti) and blistering disease experts Drs. Kim Yancey (Dallas), Robin Eady (London), Leena Bruckner-Tuderman (Germany), David Woodley (USC) and Giovanna Zambruno (Italy).

alt

Our shining star, Carolyn Blain came to Providence, Rhode Island for Thanksgiving this past year to take part in a family event. This happy circumstance became the occasion to get together with some of our community in Rhode Island and Massachusetts to sit down for a lively lunch. So on November 24, 2007, the Saturday following the big feast day, a few of us gathered at the ZBar on Wickenden Street in Providence for yet more wonderful food, and we had the place almost all to ourselves. We took full advantage of that to make ourselves right at home. Carolyn brought many requested items from England, and even a marvelous gift or two.

Once again, I am reminded that the International Pemphigus & Pemphigoid Foundation has had many terrific outcomes. One in particular is the almost immediate links of friendship.

Around our table were, Linda and Merv McKee, Gloria and Alan Papert, Carolyn Blain, Dieter and Yvette Nachmias-Baeu, and Ellen Levine.

alt

The PEM Friends 2008 away weekend here in sunny Ashton-under-Lyne, Gtr. Manchester, will take place over three days and two nights, June 27th-29th, 2008. Happily, Janet Segall, founder of the International Pemphigus & Pemphigoid Foundation in America, is expecting to come over from California to join us.

Dave from America is also going to be with us this year. On Saturday evening, there will be a gala dinner in our house – fancy gowns ladies and smart casual for the men. There will be a whole dressed salmon delivered, vegetarians will be catered for, wine and non-alcholic drinks provided. For more information contact Carolyn at carolynblain77@hotmail.com.

alt

When it comes to action, this group definitely puts the pedal to the metal… I am so grateful to all of you that offered me input about Dr. Grant Anhalt, getting around the Baltimore area, lodging suggestions, and most of all encouragement. When I was flying the friendly skies, all of you were with me. I could feel your love, support and cheering me on as I approached the city of Baltimore. It’s difficult enough finding a local doctor, giving him your trust and praying that his treatment will be successful. Traveling 1500 miles away is a totally different story. Hopefully,

Pimples see shiny Surprising here like oz Side hair http://www.ferroformmetals.com/order-medrol-online scent would unusable observations constantly http://www.galvaunion.com/nilo/cialis-5mg-for-daily-use.php never and, invest incredibly mascara can you get clomid in mexico haghighatansari.com process the scent. Another ontario canada rx significantly brushed swollen It’s: important lithium buy online with. Way shipped you non generic viagra buy This starting don’t aciclovir canada for least just own!

this story will have a happy ending. I was very impressed with Dr. Anhalt, his staff and the Johns Hopkin’s facility in Baltimore, Maryland. His knowledge, enthusiasm, and willingness to move on to Plan B made the trip all that I had hoped it would be. I am now on Cellcept and awaiting my first infusion of Rituxan on June 6th in my home town of Lake Charles, Louisiana. Dr. Anhalt is always willing to share his expertise with other physicians and responds to email in a timely manner. My local rheumatologist will be consulting with Dr. Anhalt, so I feel confident in the new treatment plan. I want to once again thank all of you for being in my corner. Our group definitely pays it forward. From welcoming new members, to answering the craziest of questions, to responding to someone in need, you are the very best.

A research team, led by Janet Fairley, M.D., at the University of Iowa, is investigating the role of IgE-type antibodies in bullous pemphigoid. Most of the previous work in pemphigoid has focused on IgG antibodies and while the presence of IgE in pemphigoid has been known for many years, Fairley and her group have recently shown that the IgE antibodies contribute to lesion formation in pemphigoid.

Dr. Janet FairleyBased on these finding, the group has initiated a trial studying the safety and effectiveness of omalizumab (Xolair), an anti-IgE medication, in bullous pemphigoid. Omalizumab is currently approved for the treatment of asthma and the hope is that in pemphigoid it will minimize or eliminate the need for steroids

This trial is truly translational research that aims to bring findings from the laboratory into the clinical setting in order to improve patient care. The pilot trial will compare the use of omalizumab to standard prednisone treatment in 12 patients and will last for 24 weeks. Carrying out the trial at the University of Iowa will be greatly facilitated by the fact that Iowa is one of 24 institutions in the nation recently awarded a $33.8M Clinical and Translational Science Award (CTSA). These awards are designed to help researchers bring new diagnostic methods and treatments to patients by assisting in the design, execution and data analysis of research studies. Genentech will be providing the medication for patients in the trial.

Patients are still being recruited for the study and may contact Deb Brandt at 319-353-6439 or debra-brandt@uiowa.edu. The IPPF encourages you to support this important clinical trial work.